Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

No results are reported in this dataset abstract, which details supplementary materials for a systematic review and meta-analysis on oral Janus kinase inhibitors' effectiveness and safety in children with alopecia areata, aiming to enhance transparency and interpretation of the main article's findings.

In this systematic review and meta-analysis on participants aged 12 and under with alopecia areata, the authors provide supplementary tables and figures, including pooled outcomes for hair regrowth and safety of oral Janus kinase inhibitors, supporting the main findings on their effectiveness and safety.

This article highlights the rising interest in Janus kinase inhibitors for alopecia areata, especially following the FDA approval of baricitinib, underscoring the need for better patient education and physician guidance in selecting appropriate treatments for hair loss.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This study analyzed Reddit discussions on JAK inhibitors and found that a small number of users contribute most of the conversational content, highlighting the need for expert oversight in interpreting health information shared online.

This review discusses the efficacy, safety, and practical aspects of using Janus kinase inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—as treatments for severe alopecia areata in an advanced practice provider context, without reporting specific study results.

The study found that systemic inflammatory markers were elevated in patients with severe alopecia areata compared to those with mild disease and healthy controls, and these markers decreased in patients who improved after JAK inhibitor therapy.

This research highlights the common and varied skin-related symptoms associated with chronic kidney disease, emphasizing that early recognition and multi-pronged management involving nephrology and dermatology can improve patient outcomes.

This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.

This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.

In this pediatric retrospective study, tofacitinib (a Janus kinase inhibitor) improved the severity of alopecia and quality of life more effectively than traditional treatment methods, with significant reductions in alopecia severity score and dermatology life quality index over 16 weeks.

This study analyzed techniques to create the popular "sun-kissed" hair look on dark-to-medium blonde (Level 5–6) tones, concluding that a 2–3 level differential, targeted placement across three cranial zones, and acidic glossing are essential for optimal results.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

In this study, researchers found that exosome-like nanoparticles isolated from Polygoni Multiflori Radix can promote hair growth in mice by modulating androgen signaling and gene expression, outperforming Minoxidil in testosterone-induced conditions.

This study found that JAK inhibitor treatment in patients with alopecia areata was associated with a lower incidence of major depressive disorder and decreased antidepressant usage.

This study found that among various JAK inhibitors for severe alopecia areata, baricitinib_4 mg demonstrated significant efficacy with high precision, while deuruxolitinib_12 mg showed the best efficacy but with wider confidence intervals, providing clinicians valuable information for treatment selection.

This study developed a method using ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MRM-IDA-EPI) for the rapid and sensitive detection of 13 JAK inhibitors in anti-alopecia cosmetics, showing excellent separation and accurate quantification with high recovery rates in tested matrices.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This study suggests an association between glyoxylic acid-containing hair-straightening treatments and acute kidney injury in young women, with urine calcium oxalate crystals observed in some cases, indicating potential nephrotoxicity. Early treatment with thiamine and pyridoxine may mitigate the severity of kidney damage.

In this case series, restarting Janus kinase inhibitors after pregnancy led to hair regrowth in women with alopecia areata, but highlights the lack of standardized treatment guidelines for those planning pregnancy.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Switching Janus kinase inhibitors helped some patients with severe alopecia areata regrow hair, but insurance issues can worsen the condition.

This study reviewed clinical trials on JAK inhibitors for alopecia areata, finding them effective for short-term hair regrowth with a favorable safety profile, but noted limited data on long-term risks like malignancies or cardiovascular events beyond two years.

This study surveyed Irish dermatologists and found that while JAK inhibitors show promising efficacy for alopecia areata, there is significant variation in practice due to the lack of specific guidelines and long-term safety data for these treatments.

This review discusses the pathogenesis of alopecia areata and the use of systemic JAK inhibitors in treating severe cases in pediatric patients, highlighting the safety of selective agents for children.

This study examined Chinese adult patients' discussions on social media about JAK inhibitors for alopecia areata, highlighting significant interest in these treatments but also concerns about efficacy, relapse, side effects, and the emotional impact of the condition.

This study concluded that patients with alopecia areata receiving Janus kinase inhibitors are not maintaining the recommended frequency of lab monitoring every three months, indicating a need for new strategies to improve adherence.

This study assessed the effectiveness of JAK inhibitors in Jordanian patients with alopecia areata, finding that while both tofacitinib and baricitinib improved SALT scores, baricitinib showed greater improvement and a trend towards better hair regrowth, particularly with longer treatment durations.

This study found that NK and CD8+ T cell infiltration may drive inflammation in androgenetic alopecia, suggesting that targeting IL-15 signaling could offer a new therapeutic approach for hair regeneration.